CereVasc
- 14/05/2024
- Series B
- $70,000,000
CereVasc, Inc. is developing the eShuntâ„¢ System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.
- Industry Medical Equipment Manufacturing
- Website https://cerevasc.com/
- LinkedIn https://www.linkedin.com/company/cerevasc/
Related People
Daniel LevangieFounder
Dan Levangie is an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics. He is founder and Managing Partner of ATOn Partners, a private investment and management consulting firm. Most recently Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-Founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013.
Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October 2007. While with Cytyc Corporation Mr. Levangie held positions that included Executive Vice President, Director and Chief Operating Officer, President and CEO of Cytyc Health Corporation, President of Cytyc Surgical Products and Chief Commercial Officer of Cytyc Corporation.
Prior to joining Cytyc Corporation in 1992 Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.
Mr. Levangie resides in Boston with his wife Joan and is a member of the board of Directors of Exact Sciences, Inc., Liposcience, Inc., Insulet Corporation, and Dune Medical Devices. Mr. Levangie is a graduate of Northeastern University in Boston is a member of the Advisory Board of the Barnett Institute and is a trustee of Excel Academy Charter School.